Credits: Canva
Happiness is influenced by a complex interplay of various chemicals in our brain, particularly four key neurotransmitters, D.O.S.E or Dopamine, Oxytocin, Serotonin, and Endorphins. These chemicals, often referred to as "happiness chemicals," are responsible for creating feelings of joy, motivation, connection, and calm.
However, when there's a deficiency in any of these, it can significantly affect our mood, energy, and overall well-being. Let’s dive into what these four neurotransmitters are, how their deficiency impacts us, and how we can boost their levels naturally.
Dopamine is often called the "motivation molecule." It plays a major role in enabling motivation, learning, and the pleasure-reward system in the brain. When we accomplish something — whether it’s finishing a project, completing a workout, or achieving a goal — dopamine gives us that sense of satisfaction and determination to continue.
When dopamine levels are low, it can lead to procrastination, low self-esteem, lack of focus, and general fatigue. A person might feel anxious, hopeless, or experience mood swings because the brain isn’t getting the reward signals it needs.
You can increase dopamine levels by setting and achieving small goals, exercising regularly, eating foods rich in L-Tyrosine (such as almonds, avocados, and eggs), and practicing mindfulness or meditation. Engaging in creative activities like writing or drawing also helps boost dopamine levels.
Oxytocin is often referred to as the "love hormone" or "cuddle hormone" because it plays a major role in social bonding and trust. It’s released when we hug, touch, or engage in other forms of physical affection. Oxytocin fosters feelings of connection and emotional intimacy, making it essential for relationships, family bonding, and even team cooperation.
A lack of oxytocin can lead to feelings of loneliness, stress, anxiety, and difficulties in forming or maintaining relationships. Low oxytocin levels are associated with feelings of isolation and disconnection from others.
You can raise your oxytocin levels through physical touch, socialising, spending quality time with loved ones, and even engaging in activities like massage or listening to soothing music. Acts of kindness, such as helping others or volunteering, also help release oxytocin.
Serotonin is responsible for feelings of well-being and contentment. It helps regulate mood, sleep, digestion, and even social behavior. People who have balanced serotonin levels often feel calm, confident, and emotionally stable. Serotonin is crucial in helping people feel valued and significant among their peers.
Low serotonin levels are linked to depression, low self-esteem, irritability, and mood swings. Individuals may feel overly sensitive to criticism, experience panic attacks, or struggle with social phobias when serotonin is deficient.
You can boost serotonin by getting regular exercise, exposing yourself to sunlight, engaging in cold showers or massages, and practicing mindfulness. Simple activities like walking in nature, meditating, or doing yoga are also effective serotonin enhancers.
Endorphins are the body’s natural painkillers. Released in response to stress, pain, or intense physical activity, they help alleviate discomfort and promote a sense of euphoria. Endorphins are what make you feel good after a workout or a hearty laugh, often referred to as the "runner's high."
Without enough endorphins, people may experience anxiety, depression, chronic pain, and insomnia. A deficiency in endorphins can make daily life feel overwhelming and physically draining.
To boost endorphins, engage in laughter, exercise, and stretching activities. Eating spicy foods or dark chocolate can also stimulate endorphin production. Regular massage therapy and meditation are other ways to naturally elevate endorphin levels.
Credit: iStock/X
Pope Leo XIV’s lung cancer diagnosis has raised questions about whether a lung nodule always signals cancer.
The 71-year-old pontiff announced in a post on X this week that doctors had detected a small, localized lung nodule during medical examinations. The nodule was detected at a very early stage, and doctors recommended surgery to remove it.
According to Vatican News, surgeons at Gemelli Hospital removed the lower lobe of his right lung using a video-assisted technique. Examination of the tissue confirmed lung adenocarcinoma, the most common subtype of non-small cell lung cancer (NSCLC), accounting for roughly 40% of lung cancer cases.
“An intraoperative histological examination confirmed the diagnosis of lung adenocarcinoma, as suspected from the preoperative examinations,” the statement said.
But does finding a lung nodule always mean cancer? HealthandMe spoke to experts to understand which nodules need further investigation and what warning signs to watch for.
Also read: Pope Leo XIV Will Undergo Lung Nodule Surgery: When Does Removal Become Necessary
A lung nodule is a small, localized spot in the lung, usually detected during a chest X-ray or CT scan. Most are benign, but some may indicate early lung cancer.
Dr Dipanjan Panda, Senior Consultant, Medical Oncology, Indraprastha Apollo Hospital, Delhi, told HealthandMe, that lung nodules can develop for several reasons, including infections, inflammation and, in some cases, cancer.
Doctors assess a nodule’s size, shape, density and growth, along with the patient's age, smoking history and other risk factors. Depending on these findings, they may recommend follow-up CT scans, PET-CT imaging or a biopsy.
“A lung nodule is not synonymous with cancer. Most nodules are benign, often related to previous infections or scarring. Their size, appearance, growth, and the patient’s risk factors determine whether surveillance with repeat CT, PET-CT, or biopsy is needed. The key is appropriate risk assessment, not panic or unnecessary testing,” Dr Karn Mehra, Senior Consultant and Unit Head, Advanced Lung Failure and Transplant Pulmonologist, Fortis Hospital, Manesar, told HealthandMe.
Read More: Lung Nodule on CT Scan? Doctors Explain When You Should Worry
Dr Raajit Chanana, Director and Senior Consultant, Medical Oncology, Dharamshila Narayana Superspeciality Hospital, Delhi, highlighted several factors that may raise concern about malignancy:
Although tobacco remains a major risk factor, lung cancer can also develop in people who have never smoked.
Dr Mehra noted that lung cancer in never-smokers is increasingly being recognized, including among younger adults. Air pollution, occupational exposures and genetic susceptibility may also contribute to the risk.
However, living in a polluted city alone does not justify annual CT scans. Screening should follow established risk criteria, particularly those based on age and smoking history. Low-dose CT can detect early lung cancer in eligible high-risk individuals, while indiscriminate scanning can lead to radiation exposure, false-positive results and unnecessary procedures.
READ: Dry Cough, Breathlessness May Not Always Be Asthma — Could It Be ILD?
Once lung cancer is confirmed, doctors determine its subtype, stage and molecular profile to guide treatment. Depending on these findings, treatment may include surgery, radiotherapy, targeted therapy, immunotherapy or chemotherapy.
For nodules not confirmed as cancer, management depends on their size, appearance, growth and the patient's risk factors. Small, low-risk nodules may require periodic CT scans, while suspicious ones may need further imaging or a biopsy. Not every nodule requires an invasive procedure.
“A lung nodule is not a cancer diagnosis, but it should never be ignored. Completing recommended follow-up scans is crucial. Quitting smoking remains one of the most effective ways to reduce lung cancer risk. Long-term smokers aged 50 and above should discuss whether they qualify for annual low-dose CT screening,” Dr Chanana said.
Credit: AI
Short-term exposure to air pollution may increase the risk of hospitalisation for several serious health conditions, including cancers and mental disorders, according to a new landmark multicountry study published in The Lancet Planetary Health.
Researchers analysed 346.5 million hospitalisation records from 949 communities across six countries and territories, which included Australia, Brazil, Canada, Chile, New Zealand and Taiwan.
The study examined the relationship between short-term exposure to fine particulate matter (PM2.5) and hospital admissions between 2000 and 2019.
The findings revealed that every 10 micrograms per cubic metre (μg/m³) increase in PM2.5 concentration was associated with an 8% higher risk of hospitalisation from any cause. It was the strongest for malignant neoplasms, or cancers, followed by mental disorders.
The researchers also found that the increased risks associated with short-term exposure could persist for up to 21 days.
Also read: Can Delhi’s Air Pollution Increase GI Cancer Risk? Doctors Report Patients As Young As 15
Among the disease categories examined, malignant neoplasms showed the strongest association with short-term PM2.5 exposure, with a 10.8% higher risk of hospitalisation for every 10 μg/m³ increase in particulate matter concentration.
It was followed by mental disorders, which showed a 10% higher risk. Other neoplasms were linked with a 9.6% increase, while nervous system diseases showed an 8.5% increase.
Respiratory diseases, that were commonly prevalent with air pollution, showed a 6.7% increase in hospitalisation risk.
These findings suggest that the health consequences of polluted air may not just be limited to lungs. They could affect people with a wide range of medical conditions.
However, the researchers assessed hospital admissions, not the occurrence of new diseases. Hence, they found that increases in PM2.5 exposure could increase the likelihood of hospitalisation among people affected by these conditions.
Also read: Delhi Smog: Can You Really Tackle Pollution Season With An N95 Mask And Air Purifier?
The researchers found that hospitalisation risks related to pollution were lower during 2010-2019 than in 2000-2009. Using the World Health Organization's daily PM2.5 guideline of 15 μg/m³ as a reference, the estimated proportion of hospitalisations due to exposure declined from 8.9% to 3.9% between the two decades.
Despite this improvement, the associations remained significant across all disease categories. The study had limitations, including substantial differences in effects across different countries and territories. Its findings also cannot automatically be generalised to regions that were not included, including India.
The researchers concluded that reducing PM2.5 exposure remains an important public health measure to lower hospitalisation risks. Cleaner transport, stricter industrial emission controls and lower reliance on polluting fuels could help limit exposure and the significant health burden that comes with it.
The researchers also said that the effects of short-term PM 2.5 exposure on hospital admissions could persist for up to 21 days after exposure.
PM2.5 refers to fine particulate matter measuring 2.5 micrometres or less in diameter. These particles can come from vehicle exhaust, industrial emissions, construction activities, power generation and the burning of fuels and biomass.
Because of their small size, PM2.5 particles can penetrate deep into the lungs, with some components entering the bloodstream. Exposure can trigger inflammation and oxidative stress, potentially affecting multiple organs.
Despite the observation, the study does not prove that short-term exposure to air pollution increases the risk of serious diseases like cancer. Stronger air-quality monitoring, improved cancer registries and studies linking data with clinical results could help researchers assess whether pollutants are associated with specific cancer types.
Studies would also need to account for other risk factors and differences in exposure across populations.
Credit: iStock
India faces a substantial hepatitis C burden, with the World Health Organization (WHO) estimating that 5.5 million to 12 million people are living with chronic hepatitis C virus (HCV) infection.
Untreated chronic HCV infection can lead to liver scarring, cirrhosis and liver cancer. Could shortening treatment by four weeks help more patients access a cure?
A multi-center trial led by researchers from the Indian Council of Medical Research (ICMR) found that an eight-week course of a commonly used antiviral combination was as effective as the standard 12-week regimen in patients without cirrhosis. Published in The Lancet, the findings could have implications for treatment costs and access to care.
The treatment combines sofosbuvir (400 mg) and velpatasvir (100 mg), two direct-acting antivirals that target the hepatitis C virus.
Also read: Punjab To Start Screening For HIV, Hepatitis B & C At De-Addiction Centres
The RESOLVE trial, led by researchers from Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, evaluated whether eight weeks of sofosbuvir and velpatasvir could match the effectiveness of the standard 12-week course.
The trial enrolled 880 patients without cirrhosis across five publicly funded hospitals in Lucknow, New Delhi and Varanasi. Half received the combination for eight weeks, while the other half received it for 12 weeks.
Among participants who completed treatment and follow-up, 98.8% in the eight-week group achieved a sustained virological response, compared with 99% in the 12-week group. This means the virus remained undetectable after treatment, indicating a cure.
The researchers found that the shorter regimen was non-inferior to the standard course, meaning it was not less effective beyond the trial's prespecified statistical margin.
The study also reported no drug-related serious adverse events or treatment discontinuations due to adverse events.
Direct-acting antivirals transformed hepatitis C treatment nearly a decade ago, making it possible to cure most patients with relatively few side effects. However, treatment costs and access remain important considerations for large public health programmes.
A 12-week course of sofosbuvir and velpatasvir costs approximately ₹15,000. Shortening treatment by four weeks could save around ₹5,000 per patient.
If adopted for a population of 60 lakh people requiring treatment, the shorter regimen could potentially save ₹3,000 crore. However, these are projected savings, and the actual impact would depend on patient eligibility, treatment costs and adoption in clinical practice.
The findings apply to patients without cirrhosis, as the trial excluded those with the condition. Patients with cirrhosis may require different treatment approaches depending on the severity of their liver disease and other clinical factors.
The trial's results do not mean that everyone with hepatitis C can switch to an eight-week course. Further evaluation and changes to relevant clinical guidance may be needed before the shorter regimen becomes routine practice.
Patients should consult their treating physician before making any changes to their prescribed treatment.
How Does Hepatitis C Spread?
Hepatitis C can cause illness ranging from mild infection to serious, long-term liver disease. Although some acute infections resolve spontaneously, chronic infection can progress to cirrhosis and hepatocellular carcinoma, a type of liver cancer.
The virus can spread through infected blood, including via shared needles and unscreened blood transfusions.
Perinatal transmission is an important route of HCV acquisition in children. Early detection can help identify infected infants and ensure appropriate follow-up.
© $2026 Times Horizon Private Limited